Operating
Accounts Payable
Pfizer Accounts Payable remained flat by 0.0% to -$117.25M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 54.2%, from -$255.75M to -$117.25M. Over 4 years (FY 2021 to FY 2025), Accounts Payable shows a downward trend with a -21.6% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ4 2025Feb 26, 2026
How to read this metric
An increase indicates the company is delaying payments to preserve cash, while a decrease indicates the company is paying down its obligations.
Detailed definition
Measures the change in amounts owed to suppliers and vendors for goods and services received. It serves as a source of i...
Peer comparison
A standard working capital metric used to assess short-term liquidity management and supplier payment terms.
Metric ID:
operating_increase_decrease_in_accounts_payable_tradeHistorical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $1.24B | $1.19B | -$300.00M | -$1.02B | -$469.00M |
| YoY Change | — | -4.1% | -125.2% | -241.0% | +54.2% |
Range-$1.02B – $1.24B
CAGR-21.6%
Avg YoY Growth-79.0%
Median YoY Growth-64.6%
Accounts Payable at Other Companies
Frequently Asked Questions
- What is Pfizer's accounts payable?
- Pfizer (PFE) reported accounts payable of -$117.25M in Q4 2025.
- How has Pfizer's accounts payable changed year-over-year?
- Pfizer's accounts payable increased by 54.2% year-over-year, from -$255.75M to -$117.25M.
- What is the long-term trend for Pfizer's accounts payable?
- Over 4 years (2021 to 2025), Pfizer's accounts payable has grown at a -21.6% compound annual growth rate (CAGR), from $1.24B to -$469.00M.
- What does accounts payable mean?
- The change in the amount of money the company owes to its suppliers.